"BMI ≥30" is no longer how the field decides who has obesity. Three major 2025 guidelines replaced the number with a question: is there excess adiposity, and is it harming the body?
DM
Reviewed by Doug Maready, MD Synthesized from the 2025 Lancet Commission, AACE/ABCD, and OMA/TOS/OAC guidance
By the numbers
75+
medical organizations worldwide endorsed the Lancet Commission's call to diagnose obesity by adiposity and organ impact — not BMI alone.
Rubino et al., Lancet Diabetes & Endocrinology, 2025
Core Concepts
The shift, in six ideas.
From "BMI ≥30 or ≥27 with comorbidity = eligible" to "confirmed excess adiposity + clinical impact = treat." Click any card for the pearls and references.
01
Why BMI Falls Short
It's a population screening tool. At the individual level it both over- and under-diagnoses obesity.
Read pearls
02
Preclinical vs Clinical Obesity
The Lancet Commission's core reframe: confirm adiposity first, then split by whether organs are affected.
Read pearls
03
The New Diagnostic Criteria
Three accepted ways to confirm excess fat — and why waist measures, not BMI, do the work.
Read pearls
04
Complication-Based Staging
AACE's ABCD model stages severity by complications, not the BMI number — and maps onto the Lancet split.
Read pearls
05
Beyond the Scale
The joint OMA/TOS/OAC guidance drops weight loss as a critical outcome — and is the first to add quality of life.
Read pearls
06
When It's Lipedema
Fat on the arms and legs points to a different diagnosis — one that must be separated from central adiposity.
Read pearls
Go Deeper
Two walkthroughs worth a full screen.
One shows the new diagnostic pathway step by step. The other unpacks the gap between what the guidelines now say and what the FDA label and insurers still require.
The New Diagnostic Pathway
Screen → confirm adiposity → assess organ impact → classify → match treatment intensity. Click each step for the reasoning.
Open walkthrough
The FDA & Insurance Gap
The guidelines moved on; labeling and prior-auth criteria haven't. Where patients fall through — and how to document around it.
Open walkthrough
Guideline sources
Rubino F, et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology Commission. 2025. — full text
Mechanick JI, et al. AACE Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease — 2025 Update. Endocrine Practice. 2025.
Alexander L, Golden A, et al. Joint clinical pharmacologic guidance on obesity (OMA / TOS / OAC). 2025.
This is a teaching summary, not medical advice. For clinical decisions, consult the primary guidelines and current FDA labeling.
Beyond the BMI Cutoff / Diagnostic Pathway
The New Pathway
From a Number to a Risk Assessment
The unifying idea across all three guidelines: diagnosis is a risk assessment, and treatment is risk reduction. Click each step to expand the reasoning.
01Screen with BMI — but stop there
+
BMI (≥30, or population/ethnicity-specific cut-offs) is a legitimate screening signal at the population level. It flags who to look at more closely.
It does not, by itself, confirm obesity in an individual — that's the error the old "≥27 with comorbidity" rule baked in.
02Confirm excess adiposity
+
Use one of three methods (Lancet Rec. 14): direct fat measurement (DXA/bioimpedance); or one anthropometric (waist circumference, waist-to-hip, or waist-to-height) plus BMI; or two anthropometrics regardless of BMI.
This is where the athlete is correctly ruled out and the low-muscle/high-fat patient is correctly ruled in.
Shortcut: at BMI >40, excess adiposity can be pragmatically assumed.
03Assess for organ/tissue impact
+
History, exam, and standard labs to find whether adiposity is actually affecting organs and tissues — or limiting day-to-day function.
This is the hinge between a risk state and a disease state.
04Classify: preclinical or clinical (and stage it)
+
No dysfunction → preclinical obesity (Lancet) ≈ Stage 1 (AACE). Risk state — monitor and reduce risk.
Dysfunction present → clinical obesity (Lancet) ≈ Stage 2 (mild–moderate) or Stage 3 (severe/multiple) by AACE.
The stage — not the BMI — sets how aggressively to treat.
05Match treatment intensity to organ dysfunction
+
Intensity tracks complications, not the scale. A BMI of 28 with real complications can justify the same intensity as a BMI of 38 with the same complications.
AACE adds complication-specific drug preferences (e.g., semaglutide for knee OA; tirzepatide for OSA; either first-line for T2DM).
Per OMA/TOS/OAC, judge success by health and quality of life, not weight loss alone.
Final synthesis
Diagnosis is based on risk assessment; treatment is focused on risk reduction. BMI screens, harmful adiposity diagnoses, and organ impact sets intensity.
References
Rubino F, et al. Lancet Diabetes Endocrinol. 2025.
Mechanick JI, et al. Endocr Pract. 2025.
Alexander L, Golden A, et al. OMA/TOS/OAC guidance. 2025.
Beyond the BMI Cutoff / FDA & Insurance Gap
The Real-World Gap
The Guidelines Moved. The Rules Didn't.
The major guideline bodies have redefined obesity around adiposity and organ impact — but FDA labeling and insurer prior-authorization criteria still run on the old BMI thresholds. Patients live in the gap between them.
Three answers to one question
What the guidelines now say
Lancet · AACE · OMA/TOS/OAC, 2025
+ Treat when there's confirmed adiposity + clinical impact, intensity matched to organ dysfunction.
What the FDA label still says
Wegovy & Zepbound indications
– BMI ≥30, or ≥27 with at least one weight-related comorbidity.
What payers require
Prior authorization
– Typically mirror the FDA label — documented BMI plus a qualifying comorbidity.
Who falls in the gap
The mismatch case
– The BMI-28 patient with real complications the guidelines would treat, but the label/payer rules may not cover.
Why the gap exists
+
FDA indications are tied to how the pivotal trials enrolled patients — by BMI thresholds. Labels change slowly and only with new regulatory submissions.
Guidelines synthesize the whole evidence base and can move faster. So the science of diagnosis has outrun the machinery of access.
How to document for coverage
+
Capture the qualifying comorbidity explicitly (e.g., prediabetes, hypertension, dyslipidemia, OSA, MASLD) — the label's "≥27 with comorbidity" pathway is often the route in.
Record waist circumference / waist-to-height ratio and any direct adiposity measure to substantiate excess adiposity beyond BMI.
Document organ/tissue impact and functional limitation — the clinical-obesity case — to support medical necessity on appeal.
What patients can ask their clinician
+
"Beyond my BMI, what does my waist measurement and metabolic workup say about my risk?"
"Do I have preclinical or clinical obesity — is anything already being affected?"
"If coverage is denied on BMI alone, what complication documentation supports an appeal?"
Bottom line
Until labeling and payer criteria catch up, the workaround is documentation: name the comorbidity, measure the adiposity, and record the organ impact the guidelines now center on.
References
FDA prescribing information: semaglutide (Wegovy) and tirzepatide (Zepbound).
Rubino F, et al. Lancet Diabetes Endocrinol. 2025.
Impact of 2025 Lancet diagnostic criteria on obesity treatment in the US. Clinical Obesity. 2026.